SOUTH PLAINFIELD & PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
Under the agreement, Rosetta Genomics will leverage its commercial infrastructure and expertise to market and sell Admera Health’s tests to oncologists and pathologists. Rosetta Genomics expects to record initial revenue from these test sales by year end, with more significant revenue expected to be generated beginning in 2015 and beyond.
Help employers find you! Check out all the jobs and post your resume.
Under the agreement, Rosetta Genomics will leverage its commercial infrastructure and expertise to market and sell Admera Health’s tests to oncologists and pathologists. Rosetta Genomics expects to record initial revenue from these test sales by year end, with more significant revenue expected to be generated beginning in 2015 and beyond.
Help employers find you! Check out all the jobs and post your resume.
